OCULAR THERAPEUTIX INC

For the period ended Dec 31, 2023. Filed Mar 11, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 11, 2024

OCUL$6.61-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)


· · Year Ended December 31,

· 2023 · 2022 · 2021
Revenue: · · ·
Product revenue, net	$57,870	$50,457	$43,522
Collaboration revenue	573	1,037	—
Total revenue, net	58,443	51,494	43,522
Costs and operating expenses:
Cost of product revenue	5,281	4,540	4,406
Research and development	61,055	53,462	50,083
Selling and marketing	40,549	39,922	35,190
General and administrative	33,940	32,224	31,880
Total costs and operating expenses	140,825	130,148	121,559
Loss from operations	(82,382)	(78,654)	(78,037)
Other income (expense):
Interest income	3,983	798	33
Interest expense	(11,338)	(7,022)	(6,671)
Change in fair value of derivative liabilities	(5,188)	13,841	78,121
Gains and losses on extinguishment of debt, net	14,190	—	—
Other income (expense), net	(1)	(1)	1
Total other income, net	1,646	7,616	71,484
Net loss	$(80,736)	$(71,038)	$(6,553)
Net loss per share, basic	$(1.01)	$(0.92)	$(0.09)
Weighted average common shares outstanding, basic	79,827,362	76,875,035	76,392,870
Net loss per share, diluted	$(1.02)	$(0.97)	$(0.98)
Weighted average common shares outstanding, diluted	85,596,594	82,644,267	82,162,102

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.